Skip to main
BNTC

BNTC Stock Forecast & Price Target

BNTC Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 80%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Benitec Biopharma Inc. is positioned favorably due to its promising advancements in developing BB-301, a therapeutic targeting Oculopharyngeal Muscular Dystrophy, reflected in highly positive interim clinical data. The increasing probability of regulatory approval has risen to 45%, indicative of a strong likelihood for accelerated market access based on observed clinical efficacy and the potential for premium pricing due to the treatment's value proposition. Additionally, the sustained improvements in patient outcomes, including enhanced swallowing capabilities, underscore the long-term therapeutic benefits of BB-301, supporting a favorable outlook for continued investment and growth.

Bears say

Benitec Biopharma Inc has reported a first quarter net loss of $0.21 per share, which, despite being better than the forecast of $0.41, highlights ongoing financial strain attributed to a higher-than-expected share count. The company faces significant risks related to its developmental therapy BB-301, including potential delays in clinical trials, negative study data, and challenges in obtaining regulatory approval, all of which could negatively affect market perception and share value. Additionally, there are concerns regarding medium- to long-term dilution risks and slower-than-anticipated market uptake for their therapeutic, contributing to the analyst's cautious outlook on the company's financial future.

BNTC has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 80% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Benitec Biopharma Limited Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Benitec Biopharma Limited Sponsored ADR (BNTC) Forecast

Analysts have given BNTC a Buy based on their latest research and market trends.

According to 5 analysts, BNTC has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Benitec Biopharma Limited Sponsored ADR (BNTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.